Komipharm International Co., Ltd.

A041960

KR7041960006

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 09/06/2024 BST			5-day change	1st Jan Change
4,120 ^KRW	+2.87%		+0.12%	-1.67%

05-29	Komipharm International Co., Ltd. announces an Equity Buyback for 481,927 shares.	CI
05-29	Komipharm International Co., Ltd. authorizes a Buyback Plan.	CI

Komipharm International Australia Pty. Ltd. announced that it has received AUD 3.58605 million in funding from Komipharm International Co., Ltd.

December 22, 2021

On December 23, 2021, Komipharm International Australia Pty. Ltd. closed the transaction.

Latest news about Komipharm International Co., Ltd.

Komipharm International Co., Ltd. announces an Equity Buyback for 481,927 shares.	05-29	CI
Komipharm International Co., Ltd. authorizes a Buyback Plan.	05-28	CI
Tranche Update on Komipharm International Co., Ltd.'s Equity Buyback Plan announced on March 21, 2024.	05-28	CI
Tranche Update on Komipharm International Co., Ltd.'s Equity Buyback Plan announced on March 21, 2024.	05-28	CI
Komipharm International Co., Ltd.'s Equity Buyback announced on March 21, 2024, has closed with 241,545 shares, representing 0.35% for KRW 987.93 million.	05-27	CI
Komipharm International Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Komipharm International Co., Ltd. announces an Equity Buyback for 241,545 shares.	03-20	CI
Komipharm International Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Komipharm International Co., Ltd. authorizes a Buyback Plan.	03-19	CI
Komipharm International Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Komipharm International Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Komipharm International Co., Ltd. announced that it has received KRW 15 billion in funding from a group of investors	05/07/23	CI
Komipharm International Co., Ltd. announced that it expects to receive KRW 15 billion in funding	03/07/23	CI
Komipharm International Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Komipharm International Co., Ltd.'s Equity Buyback announced on September 23, 2022, has expired.	22/12/22	CI
Tranche Update on Komipharm International Co., Ltd.'s Equity Buyback Plan announced on September 23, 2022.	16/12/22	CI
Komipharm International Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Komipharm International Co., Ltd. announces an Equity Buyback for 146,842 shares.	23/09/22	CI
Komipharm International Co., Ltd. authorizes a Buyback Plan.	22/09/22	CI
Komipharm International Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
Komipharm International Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
Komipharm International Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	16/03/22	CI
Komipharm International Australia Pty. Ltd. announced that it has received AUD 3.58605 million in funding from Komipharm International Co., Ltd.	22/12/21	CI
Komipharm International Australia Pty. Ltd. announced that it expects to receive AUD 3.58605 million in funding from Komipharm International Co., Ltd.	16/12/21	CI
Komipharm International Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21	CI

Chart Komipharm International Co., Ltd.

Duration

Period

More charts

Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
KOMIPHARM INTERNATIONAL CO., LTD.	-1.67%	203M
ZOETIS INC.	-9.05%	80.73B
ELANCO ANIMAL HEALTH INCORPORATED	+22.38%	9B
BLUESTAR ADISSEO COMPANY	+24.50%	3.69B
VIRBAC	+0.42%	3.28B
VETOQUINOL SA	0.00%	1.31B
JINYU BIO-TECHNOLOGY CO., LTD.	-26.00%	1.23B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-29.34%	1.18B
WUHAN KEQIAN BIOLOGY CO.,LTD	-23.11%	1B
SWEDENCARE AB	+2.61%	932M

Veterinary Drugs

Komipharm International Co., Ltd.

Equities

A041960

KR7041960006

Pharmaceuticals

Komipharm International Australia Pty. Ltd. announced that it has received AUD 3.58605 million in funding from Komipharm International Co., Ltd.

Latest news about Komipharm International Co., Ltd.

Chart Komipharm International Co., Ltd.

Company Profile

Income Statement Evolution

Sector Veterinary Drugs